Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal
Biogen agreed to pay $300m upfront to buy a Phase II-ready tau antibody from Bristol. The plan is to move rapidly into mid-stage clinical trials for Alzheimer's disease and progressive supranuclear palsy.
You may also be interested in...
Biogen Gives Up On Gosuranemab After No Benefit Seen In Alzheimer's Study
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.
Biogen’s Tau Antibody Fails In PSP, But Alzheimer’s Studies Continue
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
AbbVie's Alzheimer's Efforts Voyage Into AAV-Targeted Tau Antibodies
Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.